Jupiter Neurosciences has unveiled Nugevia MND, a new supplement formulated to enhance cognitive function and support brain health.
Nugevia MND combines Jupiter’s JOTROL resveratrol platform with NovaSOL Curcumin, both known for their bioavailability and effectiveness in neuroprotection.
It is designed to improve memory, clarity, and executive function while reducing neuroinflammation and oxidative stress.
The product also supports mitochondrial function in brain cells, potentially offering protection against age-related cognitive decline.
Jupiter Neurosciences is offering the supplement, as a two-capsule daily regimen, through e-commerce platforms from Autumn 2025.
Jupiter Neurosciences chairman and CEO Christer Rosén said: “We’ve worked extensively on our third, and in my opinion the most important, product in the Nugevia launch. It is my pleasure to introduce MND to the healthspan and longevity community.
“My mother passed away from Alzheimer’s Disease making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s Disease.
“This is personal, this is important and based on our JOTROL pharmaceutical pre-clinical and clinical date we are here to bring what we believe is the best cognition product to the market.”
JOTROL technology has shown higher bioavailability than previous resveratrol products, addressing past issues of poor absorption and gastrointestinal side effects.
The company is advancing JOTROL into a Phase 2a trial for Parkinson’s Disease, building on successful Phase 1 results, published in 2022.
Nugevia MND complements Jupiter’s therapeutic pipeline, bridging consumer and pharmaceutical segments.
Offering pharmaceutical-grade bioavailability, the supplement aims to generate high-margin revenue and meet the needs of adults seeking cognitive enhancement.
Rosén added: “The introduction of Nugevia MND represents a strategic step in leveraging our CNS therapeutic expertise within the consumer health market.
“Importantly, learnings from consumer use of MND, combined with biomarker data anticipated from our upcoming Phase II Parkinson’s disease trial, will provide valuable insights to inform our future cognitive health programs.
“What is the purpose of all the new ways with early detection of these progressive diseases if there is no good way to prevent them, stop them, or significantly slow them down? We are optimistic that our clinical studies will back up my belief that we have again cracked the code and MND is the solution.”
